According to Research Report Custom Antibody Market is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4% during the forecast period. The growth of this market is mainly driven by expanded use of antibody biomarkers identification and validation in diagnostics. Furthermore, increased R&D funding coupled with high investment by market players in custom antibody is likely to upsurge market growth in coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164328301

Browse in-depth TOC on "Custom Antibody Market “

312 – Tables

40 – Figures

277 – Pages

DRIVER: Increased Funding is likely to upsurge the market growth

Antibody development and research has gained momentum, owing to the depleting mAbs pipeline, rising incidence of chronic and debilitating disorders such as cancer and infectious diseases; and growing need to develop effective and promising cures for several diseases that adversely affect the quality of life across the globe. The continuous rise in the funding for antibody research by government agencies is further supporting the growth of this market. For instance, in April 2022, Japan invested USD 970 million in regenerative medicine, focusing on induced pluripotent stem cells (iPS) to survive with the world's oldest population. The stem cells can then be used to repair human tissues or grow organs, indirectly impacting antibody research in the country. The funding will enable the country to continue to support custom antibody startups and SMEs, strengthen the emerging asiatic bioeconomy and help unlock the societal benefits of custom antibody.

RESTRAINT: Cost and complexities associated with antibody

The development of antibodies requires detailed knowledge and qualitative considerations, which require high capital investments and time limitations. In addition, the technologies required for antibody production include large bioreactors, filtration systems, and media & buffers for upstream/ downstream processing and purification. Thus, on average, the cost to produce custom mAbs goes on increasing depending on the additional services required, based on the procedures followed by each player. While developing the site-specific antibody requires consideration of the antigen against which antibodies need to be generated, followed by their specificity and reproducibility. Thus, the cost associated with antibodies can potentially hamper the market growth to a certain extent.

OPPORTUNITY: Emerging Markets

The rising investments by emerging countries in antibody drug discovery are responsible for the growth of the global market in the region. For instance, the Australian government has allocated USD 3.6 billion in basic research to support science, research, and innovation in the country from 2020 to 2021 to develop new products for treating lung conditions, including mepolizumab, a monoclonal antibody used to treat severe asthma. While the growing incidence of infectious and chronic disorders and increasing R&D initiatives to develop innovative treatment and diagnostic options are some of the factors likely to project the use of a custom antibody in the coming years. Additionally, developments in research infrastructure and the low-cost manufacturing advantage offered by emerging countries are expected to encourage market players to invest in emerging markets like Asia Pacific during the forecast period.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=164328301

The antibody development segment accounted for the largest share of the service segment in the custom antibody market in 2022.

Based on service, the custom antibody market is broadly segmented into antibody development, antibody production & purification, and antibody labeling. In 2022, antibody development accounted for the largest share of the custom antibody market for service. This segment's large share can be attributed to factors such as the rising demand for therapeutic antibodies, which are used in a wide range of applications.

The monoclonal antibodies segment accounted for the largest share of the type segment in the custom antibody market in 2022. 

Based on type, the custom antibody market is categorized into three segments—monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. In 2022, monoclonal antibodies segment accounted for the largest share of custom antibody market. Factors such as the high degree of sensitivity and precision with the use of monoclonal antibodies in drug discovery and development are projecting the segmental growth.

Asia Pacific is likely to grow at double digit growth rate during the forecast period.

The Asia Pacific region is estimated to grow at the highest CAGR in the custom antibody market during the forecast period, this is mainly due to factors such the rising investment in research & development, increased adoption of custom antibodies for various research and diagnostics purpose, emergence of new market players in custom antibody market.

Request free sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164328301

Top of Form

Key Market Players

The prominent players operating in the custom antibody market are Thermo Fisher Scientific Inc. (US), GenScript (China), Merck KGaA (Germany), Abcam (US), and Agilent Technologies, Inc. (US).

Recent Developments:

  • In December 2022, Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.
  • In October 2022, Thermo Fisher Scientific acquired The Binding Site Group (The Binding Site), a global leader in specialty diagnostics.
  • In July 2022, Bio-Techne acquired Namocell to expand its product portfolio, to include gene therapy development and commercialization, cell engineering, cell line development, single cell genomics, and antibody discovery.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]